Literature DB >> 23396742

Intestinal mucosal proliferation, apoptosis and oxidative stress in patients with liver cirrhosis.

Stelios F Assimakopoulos1, Athanassios C Tsamandas, Georgios I Tsiaoussis, Elli Karatza, Dimitrios Zisimopoulos, Ioannis Maroulis, Eleni Kontogeorgou, Christos D Georgiou, Chrisoula D Scopa, Konstantinos C Thomopoulos.   

Abstract

BACKGROUND: Intestinal mucosal barrier dysfunction in liver cirrhosis and its implicated mechanisms is of great clinical importance because it is associated with the development of serious complications from diverse organs through promotion of systemic endotoxemia. AIM: The present study was designed to investigate whether enterocytes' proliferation, apoptosis and intestinal oxidative stress are altered in the intestinal mucosa of patients with compensated and decompensated liver cirrhosis.
MATERIAL AND METHODS: Twelve healthy controls (group A) and twenty four cirrhotic patients at a compensated (n = 12, group B) or decompensated condition (n = 12, group C) were subjected to duodenal biopsy. In intestinal specimens mucosal apoptotic and mitotic activity and their ratio were recorded by means of morphological assessment and mucosal lipid hydroperoxides were measured. Plasma endotoxin concentration, an index of gut barrier function, was also determined.
RESULTS: Cirrhotic patients presented significantly higher serum endotoxin concentrations as compared to healthy controls (P < 0.001), whilst endotoxemia was higher in decompensated disease (P < 0.05 vs. compensated cirrhosis). Intestinal mucosal mitotic count was significantly lower in patients with compensated and decompensated cirrhosis compared to controls (P < 0.01, respectively), whilst a trend towards increased apoptosis was recorded. The mitotic/apoptotic ratio was significantly reduced in groups B (P < 0.05) and C (P < 0.01) as compared to controls. Intestinal lipid peroxidation was significantly increased in decompensated cirrhotics (P < 0.001 vs. groups A and B).
CONCLUSIONS: The present study demonstrates for the first time that human liver cirrhosis is associated with decreased intestinal mucosal proliferation and proliferation/apoptosis ratio even at early stages of cirrhosis and increased intestinal oxidative stress in advanced liver disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23396742

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  17 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

Review 2.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

3.  Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH).

Authors:  Hiroki Utsunomiya; Yasunori Yamamoto; Eiji Takeshita; Yoshio Tokumoto; Fujimasa Tada; Teruki Miyake; Masashi Hirooka; Masanori Abe; Teru Kumagi; Bunzo Matsuura; Yoshio Ikeda; Yoichi Hiasa
Journal:  J Gastroenterol       Date:  2017-01-06       Impact factor: 7.527

4.  Circulating muramyl dipeptide is negatively associated with interleukin-10 in the frail elderly.

Authors:  Chris P Verschoor; Avee Naidoo; Jessica G Wallace; Jennie Johnstone; Mark Loeb; Jonathan L Bramson; Dawn Me Bowdish
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

5.  Defects in energy metabolism are associated with functional exhaustion of bone marrow mesenchymal stem cells in cirrhosis.

Authors:  Dhananjay Kumar; Deepanshu Maheshwari; Nidhi Nautiyal; Smriti Shubham; Sheetalnath Rooge; Lovkesh Anand; Ashish Vyas; Rekha Kumari; Shvetank Sharma; Chhagan Bihari; Sujata Mohanty; Rakhi Maiwall; Anupam Kumar; Shiv Kumar Sarin
Journal:  Am J Stem Cells       Date:  2022-02-15

Review 6.  Changes of Intestinal Functions in Liver Cirrhosis.

Authors:  Hiroshi Fukui; Reiner Wiest
Journal:  Inflamm Intest Dis       Date:  2016-03-08

7.  Baicalein reduces the occurrence of cirrhotic endotoxemia by reducing intestinal mucosal apoptosis.

Authors:  Yi Liu; Feng Ye; Wen-Jing Zou; Ye Sun; Rui Wang; Ping-Ping Han; Zhe Zhang; Xue-Liang Yang; Xiaojin Liu
Journal:  BMC Complement Altern Med       Date:  2015-05-29       Impact factor: 3.659

Review 8.  Increased circulatory asymmetric dimethylarginine and multiple organ failure: bile duct ligation in rat as a model.

Authors:  Jiunn-Ming Sheen; Yu-Chieh Chen; You-Lin Tain; Li-Tung Huang
Journal:  Int J Mol Sci       Date:  2014-03-05       Impact factor: 5.923

9.  Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.

Authors:  Akitoshi Douhara; Kei Moriya; Hitoshi Yoshiji; Ryuichi Noguchi; Tadashi Namisaki; Mitsuteru Kitade; Kosuke Kaji; Yosuke Aihara; Norihisa Nishimura; Kosuke Takeda; Yasushi Okura; Hideto Kawaratani; Hiroshi Fukui
Journal:  Mol Med Rep       Date:  2014-11-24       Impact factor: 2.952

10.  Metabolic endotoxaemia in childhood obesity.

Authors:  Madhusudhan C Varma; Christine M Kusminski; Sahar Azharian; Luisa Gilardini; Sudhesh Kumar; Cecilia Invitti; Philip G McTernan
Journal:  BMC Obes       Date:  2016-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.